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ABSTRACT 
 
Drug development is a challenging way to make profits. Thousands of once-promising compounds wash out in the 
preclinical phase and hundreds more fail in clinical trials and only one is likely to be approved for marketing. 
Hundreds of millions of dollars are spent on pharmaceuticals or biologics that fail to make it to market. The 
successful to reach here the market, developed in this way takes approximately 12-15 years. However, there are 
alternatives to spending enormous sums in developing drugs. One of the approach is to concentrate on developing 
products for niche markets that may have smaller market potential, but that can be approached with dramatically 
lower development costs and time using section 505(b)(2) pathway to FDA approval. The second approach is the 
request for biowaivers i.e. in vivo bioequivalence and bioavailability study waivers in accordance to the principles of 
the Biopharmaceutical Classification System (BCS) that can significantly save time and cost. Third one is the 
generic drug approval pathway in which only BA/BE studies are done comparing the proposed product to the 
innovator product. The present review apart from giving a brief overview of the above approaches highlights the 
present status and future prospective of these approaches. It also gives a brief overview of impact of these fast track 
approval procedures on the global market of medicines. 
 
Keywords: 505(b)(2) NDA, hybrid applications, reference listed drug, clinical studies, generic drugs, biowaivers, 
market exclusivity. 
 
Introduction 
 
Drug development is a process of bringing a new drug 
to the market once a lead compound has been identified 
through the process of drug discovery. It includes pre-
clinical studies, clinical studies and finally the step of 
obtaining regulatory approval to market the drug [1]. 
The full cost of bringing a new drug to market – from 
discovery through clinical trials to approval – is 
complex and controversial and is highlighted in the 
study published in 2006,  
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which estimates that costs vary from around $500 
million to $2 billion depending on the therapy or the 
developing firm (Table 1 & 2) [2]. The success rate for 
a new drug to treat a disease might theoretically 
include from 5,000 to 10,000 chemical compounds. 
Thus, new drug development is both an extensive as 
well as expensive process [3]. However, there are 
novel approaches to boost the drug development. There 
are three different approaches which can be helpful for 
developing drugs with reduced period of time and cost. 
These are as follows: 
 
1. Request for Biowaivers 
2. Generic Drug Approval Pathway 
3. 505(b)(2) NDA 
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Table 1: 505(b)(1) vs. 505(b)(2) Drug Development Timeline 
 
NDA Discovery Preclinical Research Clinical Studies 
505(b)(1) 2-5 years 1-3 years 8-15 years 
505(b)(2) <1-3 years <1-2 years 2-5 years 
 
Table 2. Comparative Analysis of Timing & Costs for 505(b)(2) NDA & ANDA 
 Estimated Duration Estimated Cost 
ANDA 
 BE study(ies) 
 Submission 
 Time to approval 
505(b)(2) NDA 
 Clinical trial(s) (if needed) 
 BE studies 
 Submission 
 Time to approval 
 
4-6 months 
1-2 months 
18+ months 
 
12-24 months 
4-6 months 
1-2 months 
10 months 
 
$50k-$750k 
 
 
 
$2m-$10+m 
$50k-$750k 
 
BE (Bioequivalence Studies), NDA (New Drug Application), ANDA (Abbreviated New Drug Application) 
 
Both FDA and EMA accept BCS based biowaivers for 
Class I drug substances, but the threshold for complete 
absorption is lower for the EMA (85% fraction 
absorbed) than the FDA (90%). The biowaiver market 
shows greater number of biowaiver submissions over 
the past three years and the wider use of in vitro test 
systems for permeability3. While 505(b)(2) NDA 
approvals are increasing at higher rates than 505(b)(1) 
approvals. In 2012, a record number of 47 505(b)(2) 
applications were approved by FDA as compared to 31 
505(b)(1) applications [4]. The global generics market 
is estimated at about $225 billion in 2011. By 2016, it 
is expected that the value of the total global generics 
sector will have risen to $358 billion, representing 
more than 18% of all pharmaceuticals, a projected 
compound annual growth rate (CAGR) of 9.7% 
between 2011 and 2016. Emerging market represents 
the second largest market category for generic drugs 
with the expected sale of $57 billion in 2011. This 
should reach nearly $115 billion in 2016, for a CAGR 
of 15.1% (Figure 2) [5]. 
 
 
Figure 2: Major Generics Markets, Through 2016 
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Definitions 
 
Biowaiver: A biowaiver is considered as the waiver of 
clinical bioequivalence studies when the active 
pharmaceutical ingredients meet certain solubility and 
permeability criteria in vitro and when the dissolution 
profile of the dosage forms meets the requirements for 
the immediate release dosage forms [6, 7]. 
 
505(b)(2) NDA: An application that contains full 
reports of investigations of safety and effectiveness but 
where at least some of the information required for 
approval comes from studies not conducted by or for 
the applicant and for which the applicant has not 
obtained a right of reference [8]. 
 
Patent: A patent is an intellectual property right, which 
gives the holder the right to exclude others from 
making, using, selling, offering for sale, or importing 
the patented product [9]. 
 
Data Exclusivity: It is a period of non-reliance and 
non-disclosure that a government must provide to 
pharmaceutical registration data [10, 11]. 
 
Market Exclusivity: It is a period between the 
approval of a drug by the regulatory authorities and the 
expiry of the patent term during which no only 
innovative company can market that drug [12]. 
 
Listed Drug: A new drug product that has an effective 
approval by the FDA and which has not been 
withdrawn or suspended or which has not been 
withdrawn from sale as reasons of safety or 
effectiveness determined by FDA is termed as a listed 
drug. Listed drug status is evidenced by the drug 
product’s identification as a drug with an effective 
approval in the current edition of FDA’s “Approved 
Drug Products with Therapeutic Equivalence 
Evaluations” or any current supplement thereto, as a 
drug with an effective approval [13]. 
 
Reference Listed Drug: The listed drug identified by 
FDA as the drug product upon which an applicant 
relies in seeking approval of its abbreviated application 
[14]. 
 
Literature: Literature in this context refers to 
published reports of well-controlled studies that 
support safety or effectiveness; prosed and final 
monographs published in the Federal Register the data  
 
supporting a Federal Register notice announcing a 
product’s safety and/or effectiveness [15]. 
 
Generic Drug: A drug product which is comparable to 
a reference listed drug product in dosage form, 
strength, route of administration, quality, performance 
characteristics, and intended use [16]. 
 
Request for Biowaivers 
The term biowaiver describes the use of an in vitro 
assessment to waive the need for in vivo (bio) studies 
[6]. It is considered as waiver of clinical 
bioequivalence studies [4,5]. It was originally proposed 
by Amidon and co-workers in 1995 [17] and 
subsequently adopted by the US FDA, WHO, and 
European medicines Agency (EMA) for 
implementation in the approval of some generic drug 
products [18-20]. Thus, pharmaceutical companies can 
request for biowaivers according to the 
Biopharmaceutical classification System (BCS) for 
NDA and ANDA filing as well as to scale-up and post 
approval changes in drug manufacturing. It is estimated 
that the in vivo bioavailability and bioequivalence 
studies cost upto $ 250,000 each and require upto 2 
months to complete, whereas, the in vitro laboratory 
tests are rather inexpensive and fast [21]. However, the 
regulations on BCS based biowaivers differ between 
the FDA, EU and WHO. The FDA allows the 
biowaiver only for BCS class I drug substances 
whereas current WHO and EMA guidances allow 
products containing class III drug substances to be 
considered for the biowaiver. 
  Other countries following the BCS based 
biowaiver concept as one of the three main guidance 
documents (US FDA, EMA, WHO) or a combination 
of specific requirements are Brazil [22], Australia, 
Association of Southeast Asian Nations (ASEAN) 
countries, South Africa [23], India [24], Argentina 
[25], Southi Arabia [26]. While Switzerland, Canada, 
Japan [27] have not yet implemented the BCS based 
biowaiver as a means to ensure bioequivalence of 
different drug products in any shape or form. 
 
Risk Associated With Using Request For BCS 
Based Biowaiver 
• Risk of bioinequivalence between a test and a 
reference drug product due to excipients 
and/or manufacturing effects. 
• Risk of approving a test product according to 
the biowaiver procedure, when infact if it was 
compared with the reference product in an 
vivo stydy it would fail to meet 
bioequivalence standards. 
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• Risk to patients associated with a false, 
biowaiver-based acceptance of a drug product, 
which would actually fail to be bioeqiuivalent 
to the comparator product in an vivo study. 
Therefore, merely classifying a drug substance 
according to the BCS is not a sufficient basis for 
determining whether products containing the substance 
can be biowaivered or not and there is a need to 
develop more stringent criteria for biowaiver [6]. 
About 30 biowaiver monographs have been 
documented up to date by the joint effort of FIP and 
WHO which are working on a running biowaiver 
monograph project. These monographs have a great 
impact on the approval of multi-source drug products 
as many applicants have submitted dossiers which refer 
to the results summarized in the monographs, without 
being asked by the regulatory agencies to repeat the 
studies, thus saving the applicants time and money [6]. 
 
Future Prospectives 
The BCS based biowaiving is an innovative technique 
which significantly saving the time and cost in the 
approval of drug products. Research is ongoing in this 
field by exploring more ways to increase the utilization 
of this technique. Some of the future prospective are as 
follows: 
• In the future, the biowaiver monograph project 
will extend to fixed dose combinations. 
• Developing science-based risk calculations to 
make the biowaiver decision more objective 
[28]. 
• A key future activity in the BCS based biowaiver 
area should be global hormonization of 
biowaiver regulations. Therefore, various 
regulatory authorities should change and 
improve their regulations, so that they will apply 
“best science” practice to BCS biowaiving [7]. 
 
Generic drug Approval Pathway 
Generic drug approval pathway is another fast track 
approach to expedite the approval of proposed drug 
product(s) by just showing bioequivalence to the 
reference listed drug. Bioequivalence is demonstrated 
through studies, which prove that the active ingredients 
work in the same way and in the same amount of time 
in the human body [29]. Generic drugs approved in this 
way are much cheaper than brand drugs and provide 
significant saving to consumers. As per global market 
trend, it is estimated that approximately $150 billion 
worth of drugs will be off-patented during the period 
2010 to 2017, which will serve as a platform for 
pharmaceutical companies to develop generic drugs 
[30]. In US, the legislation for generic drugs came into 
effect on 1984 after the enactment of the Hatch-
Waxman Act which allows generic drugs to enter the 
market without repeating extensive clinical trials 
required for their brand-name counter parts after expiry 
of the patent and certain exclusivities. The 
pharmaceutical companies seeking approval of their 
generic drug must file Abbreviated New Drug 
Application (ANDA) to FDA. The FDA after thorough 
review of the application and assuring safety and 
efficacy either approve or discard the application [31]. 
  A pre-requisite for filing ANDA is that applicant 
is required to make patent certifications for the 
reference listed drug. There are four types of patent 
certifications for which the ANDA can submit. 
1. Paragraph I certification: That the patent 
information was not submitted to FDA by the 
reference listed drug company. 
2. Paragraph II certification: That the patent has 
expired. 
3. Paragraph III certification: That the patent will 
expire on a specific date. 
4. Paragraph IV certification: That the patent is 
invalid or will not be infringed. 
  Apart from getting approval in a short period of 
time with reduced cost, the first to file ANDA 
applicant for the reference listed drug would get 180 
days market exclusivity [32]. Often the legal 
proceedings occurs between the branded and generic 
company but they may agree on a settlement and the 
180 days market exclusivity granted to the first filed 
ANDA would get delayed and further halt the entry of 
other generic drugs for that reference listed drug. 
  The Medicare Prescription Drug, Improvement, 
and Modernization Act of 2003 amended three major 
rules pertaining to listed drugs, thirty-month stays and 
approvals of ANDAs [33]. The innovator drug 
company could not further delay the entry of generic 
drugs by filing multiple patent infringement lawsuits in 
order to obtain multiple 30-monthstays. Further the 
final rule on generic drugs which became effective on 
Aug 19, 2003 would allow faster access to generic 
drugs while maintaining fair incentives for innovative 
new drug development [34]. 
In Europe, regulations for generic drugs are on similar 
principles and are set out in Article 6 of regulation 
(EC) No. 726/2004 and Article 10(1) of Directive 
2001/83/EC, as amended [35]. Generally, the 
decentralized procedure or national mutual recognition 
procedure is followed for the approval of generic drug 
products. However, at the request of an applicant, be 
accepted for consideration under the centralised 
procedure, when the applicant shows that the medicinal 
products constitute: 
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• A significant therapeutic, scientific, or 
technical innovation,  
• The granting of a Community authorization 
for the medicinal product is in the interest of 
patients at the Community level. 
In Canada, the regulatory agency Health Canada 
regulates the pharmaceutical products. Other countries 
like in Brazil, The Generics Law, 1999 and the 
ANVISA regulate the implementation of generic 
pharmaceuticals policy. In Japan, the Ministry of 
Health, Labour, and Welfare (MHLW) is in charge of 
the pharmaceutical regulatory affairs and the 
Pharmaceutical Medical Devices Agency (PMDA) and 
the generic drugs are submitted under Japanese ANDA 
to PMDA which reviews the application. While 
countries from Asia Pacific and Gulf have almost 
harmonized their regulatory environment through the 
ASEAN and Gulf Co-operation Council (GCC) 
organizations [36]. 
However, generic drug product manufacturers must 
formulate a drug product that will have the same 
therapeutic efficacy, safety, and performance 
characteristics as of its branded counterpart. 
 
505(b)(2) NDA 
Another attractive alternative for companies seeking to 
enter a drug market is 505(b)(2) pathway, often 
referred to as a “paper NDA” [37]. It was added in 
1984 as a part of the Hatch-Waxman Amendments to 
the Federal Food, Drug and Cosmetic Act, 1938, by 
FDA to encourage innovation and eliminate costly and 
time-consuming duplicative clinical studies. This 
pathway is a hybrid between the 505(j) accelerated 
pathway for generic drug applications, and 505(b)(1) as 
the standard de novo NDA pathway for proprietary 
drugs [38-40]. It allows a drug-maker to incorporate 
preexisting data, into its NDA by reference. This 
results in substantial savings in approval costs; the 
average 505(b)(2) approval costs $3-7 million, which is 
far less than the estimated $1.3 billion to bring a new 
drug to market under 505(b)(1) and achieve FDA 
approval in as little as 30 months [37].  Additionally, 
505(b)(2) applicant may qualify for three, five, or 
seven years of market exclusivity, depending on the 
extent of the change to the previously approved drug 
and the type of the clinical data included in the NDA 
than 180 days exclusivity for generic drugs approved 
under section 505(j). The analogous regulatory 
pathway in Europe also appears to be very similar to 
that of U.S. and was introduced within the Article 
10(3) of Directive 2001/83/EC in November 2001 and 
in the Regulation (EC) No. 726/2004. The analogous 
505(b)(2) applications in EU are known as Hybrid 
Applications [41]. 
Regardless of the regulatory pathway one chooses for 
approval of an NDA the FDA standards for the 
demonstration of safety and efficacy are same; it is 
only the source of information that differs between the 
two paths. It is important to understand what 
constitutes sufficient evidence and therefore which 
specific studies can be replaced by existing data for 
individual compounds. 
 
Market growth of 505(b)(2) 
In the relatively few years since clearing legal hurdles, 
the 505(b)(2) process has rendered significant changes 
on the drug development landscape. Today, as the 
patents for many blockbuster drugs expire, smart 
marketers are seeking ways to create new differentiated 
products, new market niches and marketing exclusivity 
through 505(b)(2) development programs. In the fiscal 
year 2006, approximately 20 % of new small-molecule 
drugs were approved through the 505(b)(2) process; 
two years later, more than half of the small-molecule 
new drugs approved in the U.S. were based on this 
strategy. The FDA approval statistics for NDA 
approvals and 505(b)(2) approvals alone from 1996-
2011 has been shown in Fig. 1 [38].  The average sales 
of products approved through 505(b)(2) in 2008 were 
estimated to be ~ USD 150mn. Further, these products 
were grown at a high compounded annual growth rate 
(CAGR) of 17.8% between the period 2006-08 which 
is three times higher than average growth of US 
pharmaceutical markets (6.4%) [42]. Judging from the 
rate at which investigational new drug (IND) 
applications are being filed today, it is expected that 
the percentage of 505(b)(2) approvals will be greater 
than 80% within the next few years [43]. 
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Figure 1: FDA 505(b)(2) Approval Statistics 2004-2012 (blog.camargopharma.com) 
 
 
 
 
General Advantages of 505(b)(2) type NDA 
• Marketed as branded products rather than generic 
• Relatively low risk because of existing safety and 
efficacy information 
• Lower cost due to smaller scope and number of 
potential studies 
• Increased speed due to fewer studies 
• Potential for “AB” substitutability rating in the 
Orange Book 
• Wide range of drug candidates with good market 
possibilities are available for rapid approval under 
505(b)(2) pathway 
• Potential route for biogenerics 
• Unlike ANDA not affected by discontinuation of 
RLD 
• Earns patent and exclusivity 
• Insulated from high market competition 
• Suitable approval pathway for non-infringing 
products 
• An opportunity in Drug efficacy Study 
Implementation (DESI) drugs 
 
Type of Changes Applicable Under 505(b)(2) NDA 
The 505(b)(2) approval route can be utilized for a wide 
range of products, especially for those that represent a 
limited change from a previously approved drug. The 
following are examples of changes to approved drugs 
which would be appropriate to submit as 505(b)(2) 
applications: 
• Changes in dosage form (e.g., oral to 
transdermal, lotion to foam). 
• Changes in strength (higher or lower). 
• Changes in route of administration (e.g., i/v to 
other parenteral routes). 
• Changes in formulation (e.g., excipients 
changes). 
• Changes in dosing regimen (e.g.., twice daily to 
once daily). 
• Changes in indication (e.g., a new indication). 
• A new combination product where the active 
ingredients have been previously approved. 
• Change to an active ingredient (e.g., different 
salt, ester complex, chelate, etc.). 
• New molecular entity when studies have been 
conducted by other sponsors and published                     
information is pertinent to the application (e.g., a 
pro-drug or active metabolite of an approved 
drug). 
• Change from an Rx indication to an OTC 
indication. 
• Change to an OTC monograph drug (e.g., non-
monograph indication, new dosage form). 
• Drugs with naturally derived or recombinant 
(i.e, biological) active ingredients where 
additional limited clinical data is necessary to 
show the ingredient is the same as the ingredient 
in the reference drug. 
• Bioinequivalence for drug products where the 
rate and or extent of absorption exceed or are 
otherwise different from the standards for 
bioequivalence compared to a listed drug. 
Additional studies might be required to 
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document the safety and efficacy at the different 
rate and extend of delivery [44]. 
 
Type of Changes Not Applicable Under 505(b)(2) 
NDA 
• An application that is a duplicate of a listed 
drug and eligible for approval under section 
505(j) 
• For which the only difference is lower extent 
of absorption than the reference drug  
• For which the only difference is an unintended 
lower rate of absorption than the reference 
drug 
 
Type of application submitted as a 505(b)(2) NDA 
• New chemical entity (NCE)/new molecular 
entity (NME): In case, when some part of the 
data necessary for approval is derived from 
studies not conducted by or for the applicant 
and to which the applicant has not obtained a 
right of reference. 
• Changes to previously approved drugs: For 
changes to a previously approved drug 
product, an application may rely on the FDA's 
finding of safety and effectiveness of the 
previously approved product, coupled with the 
information needed to support the change 
from the approved product. 
 
Information on which applicant can rely 
• Published Literature: If the applicant has not 
obtained a right of reference to the raw data 
underlying the published study or studies, the 
application is a 505(b)(2) application. 
• The Agency’s finding of safety and 
effectiveness for an approved drug 
 
Patent and Exclusivity criteria 
The 505(b)(2) applicant may qualify for 3 years of 
Waxman-Hatch exclusivity if one or more of the 
clinical investigations, other than BA/BE studies, was 
essential to approval of the application and was 
conducted or sponsored by the applicant. A 505(b)(2) 
application may also be granted 5 years of exclusivity 
if it is for a new chemical entity and may also be 
eligible for orphan drug exclusivity or paediatric 
exclusivity (Table 3). However, the filing or approval 
of a 505(b)(2) application may be delayed due to patent 
or exclusivity protections covering an approved 
product. Section 505(b)(2) applications must include 
patent certifications for each patent which claims the 
drug or drugs on which investigations that are relied 
upon by the applicant for approval of its application 
were conducted or which claims a use for such drug or 
drugs, that, a patent is invalid, unenforceable, or will 
not be infringed [45]. The applicant must provide 
notice of certain patent certifications to the NDA 
holder and patent owner [46]. 
Table 3: Market Exclusivities granted by U.S. FDA through 505(b)(2) process 
Priority Rank Code Extension Protection Period 
1. NCE New Chemical Entity 5 years 
2. NC New Combination 3 years 
3. NDF New Dosage Form 3 years 
4. NP New Product 3 years 
5. NPP New Patient Population 3 years 
6. ODE Orphan Drug Exclusivity 7 years 
7. PDE Paediatric Drug Exclusivity + 6 months 
 
 
Regulations for EU Hybrid Drug Applications 
Analogous to the FDA’s 505(b)(2) Pathway 
The regulatory pathway for hybrid drug applications in 
Europe also appears to be very similar to that of US 
and was introduced within the Directive 2001/83/ EC 
in November 2001 and in the Regulation (EC) No 
726/2004 [35]. In Europe, reference medicinal product 
has been granted a marketing authorisation by a 
Member State or by the Commission on the basis of a 
complete dossier, i.e. with the submission of quality, 
pre-clinical and clinical data in accordance with 
Articles 8(3), 10a, 10b or 10c of Directive 2001/83/EC 
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which is similar to FDA’s 505(b)(1) NDA pathway. 
Similarly, Article 10(2) and Article 10(3) of the 
Directive 2001/83/EC are analogous to FDA’s ANDA 
pathway and 505(b)(2) pathway respectively. 
 
Article 10(2) 
This article describes a ‘‘generic medicinal product’’ as 
a medicinal product that has the same qualitative and 
quantitative composition, the same pharmaceutical 
form and is proven to be bioequivalent to the reference 
medicinal product. The Article 10(2) allows the use of 
different salts, esters, ethers, isomers, mixtures of 
isomers, complexes or derivatives of the active 
principle as long as their safety and efficacy profile is 
equivalent to the original compound. In such cases, 
additional information providing proof of the safety 
and/or efficacy of the various salts, esters, or 
derivatives of an authorised active substance must be 
supplied by the applicant. The various immediate-
release oral pharmaceutical forms (e.g. capsules, 
tablets) shall be considered to be one and the same 
pharmaceutical form. 
Article 10(3) 
Product that do not fall under the Article 10(2), 
because bioequivalence can not be established through 
a bioavailability assessment or that are different to the 
reference medicinal product with regard to the active 
ingredient, the dose strength, dosage form/route of 
administration are considered as ‘‘hybrid’’ medicinal 
products. In this case the applicant has to provide in 
addition to the referenced data, results on appropriate 
non-clinical tests and clinical studies with the 
‘‘hybrid’’ medicinal product. 
Thus, hybrid applications, similar to 505(b)(2) NDAs, 
differ from generic applications in that the results of 
appropriate pre-clinical tests and clinical trials will be 
necessary for the following three circumstances: 
1. The strict definition of a “generic medicinal 
product” is not met; 
2. Bioavailability studies cannot be used to 
demonstrate bioequivalence; and 
3. There are changes in the active substance(s), 
therapeutic indications, strength, pharmaceutical 
form or route of administration of the generic 
product compared to the reference medicinal 
product. 
These applications will thus rely in part on the results 
of pre-clinical tests and clinical trials for a reference 
product and in part on new data. In contrast to the US 
regulations the major difference being that there is no 
provision for 3 years of exclusivity for the hybrid 
medicinal product, once the product is approved [47]. 
A comparative analysis of U.S. FDA 505(b)(2) NDA 
vs. EU Hybrid Medicinal Products has been shown in 
Table 4. 
Table 4: Comparative Analysis of U.S. FDA 505(b)(2) NDA vs. EU Hybrid Medicinal Products 
S.No. Parameters 505(b)(2) NDA EU Hybrid Medicinal Products 
1. Marketing Option Branded Not Branded 
2. Scientific Studies (i) No Preclinical Study 
(ii) Limited Clinical Study 
(i) No Preclinical Study 
(ii) Limited Clinical Study 
3. Patentability Yes No 
4. Market Exclusivity Yes No 
5. Patent Challenge Yes (in case of Para IV 
certification) 
No 
6. Potential Route for Biogenerics Yes No 
7. Fees (i) Less fees than 505(b)(1) 
NDA 
(ii) Companies with <500 
employees have the options 
to request for waiver of the 
fees for first submission 
Reduced fees than full Marketing 
Authorisation Application 
Data Exclusivity 
At the time of submission of the generic/hybrid 
application, the protection period of the reference 
medicinal product should have expired in order to 
allow the applicant to rely on the dossier of the 
reference medicinal product which is described below: 
• 8 years - Applications for generic/hybrid 
drugs cannot be submitted until expiry of 8 
years of first marketing authorization. 
However, applicants have been allowed to use 
a reference product’s data in compiling their 
own dossiers to obtain their own regulatory 
approvals after 8 years. 
• 10 years (8 + 2) - Generic/hybrid drugs may 
not be sold in EU until 10 years have elapsed 
from the granting of the initial marketing 
authorization. 
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• (8+2+1) - Further one year extension if 
original authorization holder obtains 
additional authorization for a new therapeutic 
use of the product resulting in clinical benefits 
[48]. 
 
Conclusions 
As the healthcare expenditure is increasing day by day, 
the pharmaceutical companies are shifting towards the 
shorter and less costly ways i.e. fast track approaches 
for developing drugs. The fast track approaches 
described above i.e. generic drugs approval pathway, 
request for biowaivers and 505(b)(2) NDA are 
economical approaches particularly for niche markets.  
Although there is a continuous process of 
harmonization of regulations taking place all around 
the world, still we see a huge challenge, which is yet to 
be overcome by the pharmaceutical industry in these 
cases. This is due to the heterogeneity in the regulatory 
landscape of the various countries. 
The BCS based biowaiver have had a great impact on 
approval of multisource drug products. Drug products 
approved through the BCS biowaiver procedure and 
manufactured under Good Manufacturing Practice can 
be assumed to have the same quality as the reference 
product. In case of biowaivers, although there are a 
number of scientific opportunities to expand the use of 
biowaivers in the future, one of the greatest advances 
would probably be an international harmonization of 
possibilities to apply biowaivers. Further, a great 
opportunity to expand the usage of biowaivers would 
be to distinguish between testing for regulatory 
approval of generic products and approval of changes 
within a given product.  
In case of generic drugs, the savings associated with 
the policies that encourage the utilization of low-cost 
generic drugs make them an obvious choice in struggle 
to contain health care costs. However, policymakers 
and researchers should address the questions 
surrounding the therapeutic equivalence of generic 
drugs. 
 While the third fast track approach i.e 505(b)(2) NDA 
process particularly attractive to investors because the 
product differentiation can provide significantly better 
market potential. However, the criteria to determine, 
what type of additional or “bridging” data needed to 
support the proposed change of the previously 
approved drug is still under question because this is 
determined on a case by case basis. To overcome this 
problem, proper meeting between the sponsors and 
regulatory professionals of FDA before filing 505(b)(2) 
application might be helpful for sponsors seeking 
505(b)(2) approval. Further, there is a need of 
harmonization of 505(b)(2) regulations across the 
world to overcome the duplication of work for 
approving drugs in different regions. 
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